Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUSION MM-003: durvalumab + daratumumab in relapsed and refractory multiple myeloma
2016-001209-17Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- May 2016
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and daratumumab in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoint: Overall response rate. Started May 2016; status: completed.
02
Drugs
durvalumabdaratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2016-001209-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001209-17.